Provided by Tiger Trade Technology Pte. Ltd.

INNOCARE

14.270
-0.400-2.73%
Volume:9.75M
Turnover:140.05M
Market Cap:25.22B
PE:32.19
High:14.850
Open:14.000
Low:14.000
Close:14.670
52wk High:20.180
52wk Low:9.650
Shares:1.77B
HK Float Shares:1.49B
Volume Ratio:1.25
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.443
ROE:12.77%
ROA:4.28%
PB:2.82
PE(LYR):32.19
PS:7.77

Loading ...

Press Release: InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

Dow Jones
·
Mar 25

InnoCare Pharma Turns to 2025 Profit

MT Newswires Live
·
Mar 25

InnoCare Updates Nomination Committee Charter to Strengthen Board Oversight and Diversity

Bulletin Express
·
Mar 25

InnoCare Pharma Publishes Updated Terms of Reference for Compensation Committee

Bulletin Express
·
Mar 25

InnoCare Proposes Sixth Amended Articles to Introduce Treasury Shares, Hybrid Meetings and E-Dividends

Bulletin Express
·
Mar 25

InnoCare Pharma Updates Audit Committee Charter to Strengthen Financial Oversight and Governance

Bulletin Express
·
Mar 25

InnoCare Announces Company Secretary Transition Effective 25 March 2026

Bulletin Express
·
Mar 25

INNOCARE Announces Appointment of Lian Shao'e as Company Secretary and Authorized Representative

Stock News
·
Mar 25

Innocare Reports 2025 Financial Results: Achieves Profitability with Net Income of Approximately 644 Million Yuan

Stock News
·
Mar 25

InnoCare redistributes RMB 2.78 billion STAR-Market IPO funds; key R&D project ICP-248 receives larger allocation

Bulletin Express
·
Mar 25

InnoCare Posts First-Ever Profit: 2025 Revenue Jumps 135% to RMB 2.37 Billion

Bulletin Express
·
Mar 25

Innocare Shares Climb Over 5% on Milestone in VAV1 Degrader Trial

Stock News
·
Mar 17

The Bull Case For InnoCare Pharma (SEHK:9969) Could Change Following First-in-China VAV1 Degrader Trial Start

Simply Wall St.
·
Mar 17

InnoCare Pharma (09969) Sets 25 March 2026 Board Meeting to Approve FY2025 Results

Bulletin Express
·
Mar 12

Assessing InnoCare Pharma (SEHK:9969) Valuation After Priority Review Milestone For Zurletrectinib

Simply Wall St.
·
Mar 08